The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2025

Filed:

Feb. 23, 2021
Applicant:

Board of Regents, the University of Texas System, Austin, TX (US);

Inventors:

Mariano A. Garcia-Blanco, Galveston, TX (US);

Gaddiel Galarza-Munoz, Galveston, TX (US);

Simon G. Gregory, Durham, NC (US);

Farren B. S. Briggs, Cleveland Heights, OH (US);

Lisa F. Barcellos, El Cerrito, CA (US);

Shelton S. Bradrick, Galveston, TX (US);

Irina Evsyukova, Cedar Grove, NC (US);

Dennis C. Ko, Durham, NC (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/34 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6883 (2018.01); C12Q 1/683 (2018.01); C12Q 1/6851 (2018.01); C12Q 1/686 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); C12Q 1/34 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/683 (2013.01); C12Q 1/6851 (2013.01); C12Q 1/686 (2013.01); C12Q 2600/156 (2013.01); C12Y 306/04013 (2013.01);
Abstract

The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.


Find Patent Forward Citations

Loading…